| Budget Amount *help |
¥17,810,000 (Direct Cost: ¥13,700,000、Indirect Cost: ¥4,110,000)
Fiscal Year 2015: ¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2014: ¥5,980,000 (Direct Cost: ¥4,600,000、Indirect Cost: ¥1,380,000)
Fiscal Year 2013: ¥8,450,000 (Direct Cost: ¥6,500,000、Indirect Cost: ¥1,950,000)
|
|---|
| Outline of Final Research Achievements |
We examined the most promising Abeta oligomer hypothesis for therapeutic drug development of Alzheimer's disease. By additional introduction of human tau into an Abeta-oligomer mouse, we succeeded in making a new model to mimic Alzheimer's disease. Furthermore, we found an improvement effect with ability for space recognition or other pathological changes to rifampicin by the drug dosage experiment using the model. Hence, we believe that the Abeta oligomer is certificated with the new model, which are supposed to be suitable for future drug screening.
|
